Skip to main content

A phase 3 randomized study of magrolimab, an anti-CD47 monoclonal antibody, in combination with venetoclax and azacitidine in newly diagnosed patients with AML

Forty Seven

TAP Partner

Project Term: July 17, 2019 - April 7, 2020

In July 2019, LLS expanded its partnership with Forty Seven by making an equity investment to support "ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-naïve Patients With Higher Risk Myelodysplastic Syndrome."

LLS funded Stanford University researchers and founders of Forty Seven, Irv Weissman, MD, and Ravi Majeti, MD, PhD, to study seminal work in macrophages. Forty Seven was a clinical-stage immuno-oncology company that was developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Gilead Sciences acquired Forty Seven in March 2020 and continues to develop magrolimab in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors.

Magrolimab is a first-in-class monoclonal antibody against the CD47 receptor. Magrolimab is currently being investigated in a Phase 3 clinical study in combination with venetoclax and azacitidine for newly diagnosed patients with acute myeloid leukemia (NCT05079230).

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects